News

Former Yahoo! Chairman, Wall Street Titan Roy J. Bostock Joins GID BIO as Chairman

Bostock joins late-stage biotech as pivotal Phase III trial gets underway for cellular therapy for osteoarthritis of the knee LOUISVILLE, Colo., July 28, 2020 -- Roy J. Bostock, former Chairman of Yahoo!, Vice Chairman of Delta Airlines and a director of Morgan Stanley, has joined the cellular medicine startup GID BIO that has a potentially break-through treatment for osteoarthritis in late-stage regulatory review. Bostock was elected chairman of the board...

Learn More

News

06/30/20

Tulane University School of Medicine announces pivotal / Phase III clinical trial for patients with knee osteoarthritis

The Tulane University Department of Orthopedics is testing a potential cellular therapy treatment for one of the world’s most common, disabling, painful musculoskeletal conditions, osteoarthritis. In New Orleans WWL-TV announced the launch of a pivotal / Phase III clinical trial to test the safety and efficacy of our point-of-care cellular therapy which intends to treat pain and function associated with knee osteoarthritis. Participants in the clinical trial undergo an out-patient...

Learn More

News

05/15/20

Aerospace to cellular therapy: How GID BIO’s CEO used his expansive engineering background to help design a scalable device for cellular therapy

An interview with William W. Cimino, Ph.D. The beginning Ten years ago, the founders of GID were looking for a CEO. They made the connection between cell therapy, fat tissue and your background but you didn’t think you were the right person. What happened next? I didn’t think I was a strong fit because I saw the position as requiring a significant background in cell biology, which I didn’t have....

Learn More

News

04/17/20

Beyond knee osteoarthritis: GID explores cellular therapy to potentially treat dermal, organ and more musculoskeletal diseases

From the bark of the willow tree 3,500 years ago that Egyptians and Sumerians popularized for pain relief, medicine is one industry that can be counted on for constant innovation over the centuries. Today, cellular therapy is the pillar of modern medicine, building on drugs and devices/surgery that have dominated medical care for the last 200 years. Cellular therapy is precision medicine and propels forward numerous paths to potentially treat...

Learn More

News

03/30/20

GID BIO addresses a growing need for cost-effective U.S. osteoarthritis treatments

The number of total knee replacement (TKR) surgeries is increasing annually, leaving experts concerned that by 2030 there may not be enough orthopedic surgeons to handle the growth. Existing alternatives to manage pain for patients with knee osteoarthritis include hyaluronic acid (HA) injections or corticosteroid (CS) injections which may be toxic to cartilage according to a Radiology report. Chris Schenk, a San Antonio realtor and avid tennis player, tried an...

Learn More

News

03/2/20

American Journal of Sports Medicine publishes results of a clinical trial for treating osteoarthritis knee pain

Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees Louisville, Colo., New Orleans, San Antonio, Chicago – March 2, 2020 /PRNewswire/ -- GID BIO announced today that The American Journal of Sports Medicine published results of its multi-site, randomized, placebo-controlled Phase IIb clinical trial measuring the safety and efficacy of its SVF-2 device and point-of-care (POC) therapy intended...

Learn More

News

01/20/20

GID BIO seeks up to USD 25m to support cellular therapy platform, CEO says

Mergermarket is the leading provider of forward-looking M&A intelligence and data to investment banks, private equity firms, law firms, accounting firms, corporates and other M&A professionals around the world. WWW.MERGERMARKET.COM January 16, 2020 by Deb Balshem GID BIO, a privately held cellular therapy company, is looking to raise between USD 20m and USD 25m to support a pivotal Phase 3 trial and potential commercialization, said CEO William Cimino. Louisville,...

Learn More

News

01/18/20

An interview with William Cimino, PhD, CEO GID BIO, International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France

GID BIO CEO William Cimino, PhD sat down with SmartTRAK, BioMedGPS Senior Analyst, Regenerative Medicine at the International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France. Click here to listen to the full interview.

Learn More

News

01/17/20

Physicians: advancing the future of evidence-based cellular therapy could increase quality of life for 14 million US adults suffering from knee osteoarthritis

Over the past three decades cardiothoracic procedures have significantly shifted to minimally invasive techniques with new technology, training of physicians and an ecosystem for workforce development. Orthopedics is on the forefront of a similar shift. Fourteen million U.S. adults suffer from knee osteoarthritis and professional athletes are driving a demand for alternative treatments to surgery, despite many being unsupported by data and lacking proof of success. This level of patient...

Learn More

News

01/14/20

Leaders come together for the first time to advance the field of cellular medicine and its treatment of pain and function associated with knee osteoarthritis

A first-of-its kind meeting brought leaders from eight orthopedic, sports medicine, pain management and regenerative medicine advocacy organizations together to discuss advancing cellular medicine in the U.S. The group of physicians, lawyers, engineers, PhDs, and CEOs from American Medical Society for Sports Medicine, Arthritis Foundation, Arthritis National Research Foundation, BoneSmart, Interventional Orthopedics Foundation, Regenerative Medicine Foundation and Regenerative Outcomes, realized the potential of combining forces to address: evidence-based data, FDA...

Learn More

News

01/10/20

Device and cellular therapy could lead to a major development in the treatment of pain and function associated with knee osteoarthritis for 14 million US adults

Individuals who overuse their joints, such as athletes, military members and people working physically demanding jobs are at a high risk of developing knee osteoarthritis (OA), according to the Arthritis Foundation. Unfortunately, there is no cure on the market for the 14 million US adults suffering. Industry experts say patients undergo 966,000 total knee replacement surgeries (TKR) annually, millions of hyaluronic and corticosteroid injections, and take millions of pain medications...

Learn More

News

01/10/20

GID BIO aims to make treatment for pain and function associated with knee osteoarthritis accessible to millions with a single-use device and point-of-care therapy

Osteoarthritis (OA) of the knee is a painful disease that impacts 14 million U.S. adults. With no surgical or pharmaceutical treatment existing to cure the disease, industry experts say patients undergo 966,000 total knee replacement surgeries (TKR) annually, millions of hyaluronic and corticosteroid injections, and take millions of pain medications. The average cost of a TKR with included basic inpatient fees is around $57,000. This figure does not include pre-...

Learn More

Previous 1 2 3 Next